Sangamo Therapeutics, Inc. (SGMO) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $0.13 (+7.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 31, 2024 | Maury Raycroft | Jefferies | $3.00 | +2245.6% |
| Dec 31, 2024 | Yanan Zhu | Wells Fargo | $2.00 | +1463.7% |
| Jun 13, 2022 | Andreas Argyrides | Wedbush | $5.00 | +3809.3% |
| Apr 5, 2022 | Nicole Germino | Truist Financial | $19.00 | +14755.4% |
Top Analysts Covering SGMO
SGMO vs Sector & Market
| Metric | SGMO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +5568.5% | +1143.3% | +14.9% |
| P/E Ratio | -0.55 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $15M | $15M | $15M | 2 |
| 2026-09-30 | $13M | $13M | $13M | 1 |
| 2026-12-31 | $13M | $13M | $13M | 1 |
| 2027-03-31 | $20M | $20M | $20M | 1 |
| 2027-06-30 | $22M | $22M | $22M | 1 |
| 2027-09-30 | $23M | $23M | $23M | 1 |
| 2027-12-31 | $29M | $29M | $29M | 1 |
| 2028-12-31 | $176M | $264M | $398M | 3 |
| 2029-12-31 | $265M | $396M | $597M | 2 |
| 2030-12-31 | $361M | $540M | $813M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.07 | $-0.07 | $-0.07 | 1 |
| 2026-09-30 | $-0.07 | $-0.07 | $-0.07 | 1 |
| 2026-12-31 | $-0.06 | $-0.06 | $-0.06 | 1 |
| 2027-03-31 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2027-06-30 | $-0.03 | $-0.03 | $-0.03 | 1 |
| 2027-09-30 | $-0.03 | $-0.03 | $-0.03 | 1 |
| 2027-12-31 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-12-31 | $0.18 | $0.25 | $0.32 | 2 |
| 2029-12-31 | $0.28 | $0.49 | $0.81 | 1 |
| 2030-12-31 | $0.43 | $0.76 | $1.27 | 1 |
Frequently Asked Questions
What is the analyst consensus for SGMO?
The consensus among 2 analysts covering Sangamo Therapeutics, Inc. (SGMO) is Buy with an average price target of $7.25.
What is the highest price target for SGMO?
The highest price target for SGMO is $19.00, set by Nicole Germino at Truist Financial on 2022-04-05.
What is the lowest price target for SGMO?
The lowest price target for SGMO is $2.00, set by Yanan Zhu at Wells Fargo on 2024-12-31.
How many analysts cover SGMO?
2 analysts have issued ratings for Sangamo Therapeutics, Inc. in the past 12 months.
Is SGMO a buy or sell right now?
Based on 2 analyst ratings, SGMO has a consensus rating of Buy (2.50/5) with a +5568.5% upside to the consensus target of $7.25.
What are the earnings estimates for SGMO?
Analysts estimate SGMO will report EPS of $-0.07 for the period ending 2026-06-30, with revenue estimated at $15M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.